April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Intravitreal Ranibizumab Outcomes in the Exsudative Age Related Macular Degeneration Treatment
Author Affiliations & Notes
  • A. Robin
    Ophthalmology, Regional hospital center bon secours, Metz, France
  • T. Maalouf
    Ophthalmology, CHU Brabois, Vandoeuvre Les Nancy, France
  • J. George
    Ophthalmology, CHU Brabois, Vandoeuvre Les Nancy, France
  • K. Angioi
    Ophthalmology, CHU Brabois, Vandoeuvre Les Nancy, France
  • Footnotes
    Commercial Relationships  A. Robin, None; T. Maalouf, None; J. George, None; K. Angioi, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4951. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Robin, T. Maalouf, J. George, K. Angioi; Intravitreal Ranibizumab Outcomes in the Exsudative Age Related Macular Degeneration Treatment. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4951.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess intravitreal (IVT) Ranibizumab effects on visual acuity (VA) and central macular thickness in exsudative age-related macular degeneration (AMD)

Methods: : Retrospective, monocentric study of a consecutive cohort treated with intravitreal Ranibizumab for exsudative AMD for which VA (Snellen chart) and central macular thickness (measured by OCT) were followed.

Results: : 62 patients (65 treated eyes) were included, mean age was 65 +/- 8 years old, 57% were women. The mean number of IVT injection was 3+/-1.7. Clinical examination was performed at 1 month and every 3 months with an average follow-up was 12 months. Initial VA was 20/80 (mean log MAR = 0.705 +/- 0.348) and remained unchanged at follow-up (20/80, mean log MAR = 0,770 +/- 0,425; p = 0.41). By contrast, a statistically significant decrease of the central macular thickness was observed (334.87 +/- 136.31 vs 251.85 +/- 139.73 micrometers; p<0.001). No induced-IVT side effects were reported.

Conclusions: : The main randomized clinical trials (MARINA, ANCHOR and PrONTO) found VA improvement that we did not reach in our cohort with only VA stabilization. This could be explain by the far less number of IVT performed in our population. Conversely, our results compared favorably for the evolution of the retinal thickness. Our present results suggest that a more pronounced effect on VA could be achieved with a more sustained follow-up with repeated IVT injection if needed in order to improve visual prognosis.

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×